🇺🇸 FDA
Patent

US 8680066

Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject

granted A61KA61K31/166A61K31/4155

Quick answer

US patent 8680066 (Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject) held by The United States of America as represented by the Development of Veterans Affairs expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Development of Veterans Affairs
Grant date
Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/166, A61K31/4155, A61K31/4184, A61K31/426